AMN Healthcare Services enters the post-earnings week as one of healthcare staffing's more charged setups. Shorts are covering aggressively after a 38% single-day explosion on May 7. The Street is chasing price targets higher. And borrow costs just doubled — all in the same five trading days.
The earnings catalyst was dramatic. AMN jumped 38% on May 7 after reporting Q1 results that beat estimates by $0.50 on EPS and benefited from a labour-disruption tailwind in its nurse and allied solutions business. The stock closed Tuesday at $29.47, up 38% for the week and 65% over the trailing month. That kind of move reshapes the short thesis in real time — and the data shows shorts responding fast.
Short sellers have been cutting positions all week. Short interest as a percentage of the free float fell from 7.2% on May 6 to 6.1% by Tuesday's close — a drop of roughly 16% over the past month and 13% in the week alone. That unwind has been orderly rather than panicked. But it is consistent and directional: shorts held firm through April, peaking above 7.2% at the start of May, then reversed sharply once the print hit. The ORTEX short score has followed, sliding from 43.9 on May 6 to 38.9 by May 12 — the lowest reading in the recent series.
The lending market tells a more complicated story. Borrow costs more than doubled in a single session on May 12, jumping from 0.42% to 0.87% — the highest level since early April and up 121% week-on-week. That CTB spike is notable precisely because availability remains very loose. The borrow pool is far from exhausted; most shorts who want out can exit without a squeeze. The doubling of cost in one day is therefore less about scarcity and more about demand: new shorts are being added even as existing ones cover, creating a crosscurrent in the lending market. Availability is currently generous enough that neither side faces a structural constraint, but the CTB direction bears watching.
Options positioning has shifted modestly toward caution but without alarm. The put/call ratio moved to 0.37 by Tuesday, roughly 1.7 standard deviations above its 20-day mean of 0.32. That is elevated compared with recent weeks — AMN's PCR was below 0.27 through most of April — but it remains far below the 52-week high of 1.41. Traders are buying modest protection after a 65% one-month run, which is rational, but the market is not pricing in a reversal.
The Street scrambled to catch up with price action this week. UBS raised its target from $19.50 to $32 on May 13, maintaining Neutral — a meaningful upgrade in absolute terms even without a rating change. BMO Capital and Baird both lifted targets to $26 on May 11, with BMO holding Outperform and Baird staying at Neutral. Truist Securities also raised to $26 while keeping its Buy. The mean price target now sits at approximately $26.86, which sits modestly below Tuesday's close of $29.47. That gap — where the stock trades above consensus target — is a common post-squeeze dynamic. The bulls point to AMN's track record of beating estimates by wide margins, particularly on EBITDA, and the potential for ongoing labour disruption to sustain elevated temporary staffing demand. Bears note that Q2 guidance signals normalization ahead, physician and leadership solutions revenues are still declining double digits year-on-year, and operating margins are tightening. EPS momentum scores of 94 and 98 over 30 and 90 days respectively are exceptional, but they describe what has happened — not what a normalization quarter delivers.
Institutional holders are broadly stable. BlackRock remains the largest holder at 15.2% of shares. Boston Partners added aggressively in Q1 — over 1.1 million shares — bringing its stake above 5.5%. Millennium and D.E. Shaw both hold positions of around 5% and 4% respectively, though their last reported dates trail the earnings event. What to watch from here is whether the stock can hold above consensus targets after the post-earnings premium fades, and whether the CTB spike on May 12 marks the arrival of fresh shorts re-entering at higher levels — or simply a one-day anomaly in a thinning borrow pool.
See the live data behind this article on ORTEX.
Open AMN on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
